UK Dry Powdered Inhaler Market

UK Dry Powdered Inhaler Market Size, Share & Trends Analysis Report by Type (Preventive Inhaler, Reliever Inhaler, and Long-Acting Bronchodilators Inhaler), by Application (Asthma and Chronic Obstructive Pulmonary Disease (COPD)), by End-User (Homecare and Hospitals and Clinics) and Forecast 2019-2025
    Update Available - Forecast 2024-2030   

Published: Jan 2020 | Report Code: OMR2020328 | Category : Medical Devices | Delivery Format: /

UK dry powdered inhaler market is anticipated to grow at a substantial rate of around 1.2% during the forecast period. The dry-powder inhaler (DPI) is used to deliver medication to the lungs in the dry powder form. It finds a significant role to treat respiratory diseases including asthma, bronchitis, emphysema, and COPD. As the prevalence of asthma and other respiratory diseases increases across UK, the demand for dry powdered inhalers is also expected to increase for treatment purposes. As per the International Monetary Fund GDP of the country was $2.9 trillion in 2017. UK comprises England, Scotland, Wales and Northern Ireland. The total population of the country in 2017 was 65 million, out of which about 18% are of the geriatric population. Mortalities related to asthma and COPD are high in UK and due to these a significant investment by the government and people can be forecast in the near future.

UK dry powdered inhaler market is segmented based on type, application, and end-user. Based on the type, preventive, reliever, and long-acting bronchodilators dry powdered inhalers are analyzed. The preventive dry powdered inhaler segment led the global dry powdered inhaler market in 2018. Preventive inhalers are most widely used in the treatment of asthma in children and adults. These inhalers do not entail side effects for long-term use, and exceptionally decreases the possibility of an asthma exacerbation. The preventive inhalers further reduce the airways swelling and hence, are recommended for regular use by the physician. Some of the preventive inhalers available in the market include Budesonide and Fluticasone. Moreover, based on the application, the market has been classified into asthma and COPD diseases. In addition, based on the end-user, homecare and hospitals and clinics have been analyzed.

Furthermore, the market is characterized by the presence of several manufacturers that are developing and providing dry powdered inhalers to cater to a wide range of customers within the region and across the globe. The major players of the UK dry powdered inhaler market include Boehringer Ingelheim International GmbH, AstraZeneca PLC, GlaxoSmithKline PLC, Novartis AG, Teva Pharmaceuticals Industries Ltd., Koninklijke Philips N.V., and Bespak. These players adopt various strategies to capitalize on market growth opportunities. Mergers and acquisitions, product launch, geographical expansion, partnerships, and collaborations are the majorly adopted strategies by the market players. 

Research Methodology

The market study of the UK dry powdered inhaler market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings the authenticity of our reports.

Secondary Sources Include:

  • Financial reports of companies involved in the market
  • Whitepapers, research-papers, and news blogs
  • Company websites and their product catalog

The report is intended for dry powdered inhaler manufacturers, contract research organizations (CROs), healthcare sector, market research firms, and government organizations, for overall market analysis and competitive analysis. The report provides an in-depth analysis of the market size and growth opportunities. The report will serve as a source for 360-degree analysis of the market thoroughly delivering insights into the market for making better business decisions.

Market Segmentation:

1. UK Dry Powdered Inhaler Market Research and Analysis by Type

2. UK Dry Powdered Inhaler Market Research and Analysis by Application

3. UK Dry Powdered Inhaler Market Research and Analysis by End-User

The Report covers:

  • Comprehensive research methodology of the UK dry powdered inhaler market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the UK dry powdered inhaler market.
  • Insights about market determinants which are stimulating the UK dry powdered inhaler market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

1. Report Summary

1.1. Research Methods and Tools

1.2. Market Breakdown

1.2.1. By Segments

2. Market Overview and Insights

2.1. Scope of the Report 

2.2. Analyst Insight & Current Market Trends

2.2.1. Key Findings

2.2.2. Recommendations

2.2.3. Conclusion

2.3. Rules & Regulations

3. Competitive Landscape

3.1. Company Share Analysis

3.2. Key Strategy Analysis

3.3. Key Company Analysis

3.3.1. Overview

3.3.2. Financial Analysis

3.3.3. SWOT Analysis

3.3.4. Recent Developments

4. Market Determinants

4.1. Motivators

4.2. Restraints

4.3. Opportunities

5. Market Segmentation

5.1. UK Dry Powdered Inhaler Market by Type

5.1.1. Preventive Inhaler

5.1.2. Reliever Inhaler

5.1.3. Long Acting Bronchodilators Dry Powdered Inhaler 

5.2. UK Dry Powdered Inhaler Market by Application

5.2.1. Asthma 

5.2.2. Chronic Obstructive Pulmonary Disease (COPD)

5.3. UK Dry Powdered Inhaler Market by End-User

5.3.1. Homecare

5.3.2. Hospitals and Clinics

6. Company Profiles

6.1. 3M Co.

6.2. Acorda Therapeutics, Inc.

6.3. Adamis Pharmaceuticals Corp.

6.4. Adherium Ltd.

6.5. AstraZeneca PLC

6.6. Bespak

6.7. Boehringer Ingelheim International GmbH

6.8. Chiesi Farmaceutici S.P.A.

6.9. GF Health

6.10. GlaxoSmithKline PLC

6.11. H&T Presspart Manufacturing Ltd.

6.12. Koninklijke Philips N.V.

6.13. Novartis AG

6.14. Omron Healthcare Inc.

6.15. ResMed Corp.

6.16. Pulmatrix Inc.

6.17. Savara, Inc.

6.18. Teicos Pharma Ltd.

6.19. Teva Pharmaceuticals Industries Ltd.

6.20. Vitalograph Ltd.

1. UK DRY POWDERED INHALER MARKET RESEARCH AND ANALYSIS BY TYPE, 2018-2025 ($ MILLION)

2. UK DRY POWDERED INHALER MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2018-2025 ($ MILLION)

3. UK DRY POWDERED INHALER MARKET RESEARCH AND ANALYSIS BY END-USER, 2018-2025 ($ MILLION)


1. UK DRY POWDERED INHALER MARKET SHARE BY TYPE, 2018 VS 2025 (%)

2. UK DRY POWDERED INHALER MARKET SHARE BY APPLICATION, 2018 VS 2025 (%)

3. UK DRY POWDERED INHALER MARKET SHARE BY END-USER, 2018 VS 2025 (%)